ImmunoGen, Inc. (IMGN)


-0.06 (-1.37%)
Symbol IMGN
Price $4.31
Beta 1.173
Volume Avg. 3.79M
Market Cap 950.510M
Shares () -
52 Week Range 3.1-7.77
1y Target Est -
DCF Unlevered IMGN DCF ->
DCF Levered IMGN LDCF ->
ROE -66.56% Strong Sell
ROA -26.86% Sell
Operating Margin -
Debt / Equity 57.18% Buy
P/E -
P/B 3.56 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest IMGN news

Mr. Mark Enyedy
NASDAQ Global Select

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.